检索结果-南通市图书馆

Omics methods predict the prognosis and treatment efficacy of chronic obstructive pulmonary disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第3期137卷 356-358页

作者： Yan Huang Juanjuan Xu Guanzhou Ma Sufei Wang Xiaojuan Yan Yang Jin Jiafu He department of Respiratory and critical care medicine Xiangyang Central HospitalAffiliated Hospital of Hubei University of Arts and ScienceXiangyangHubei 441000China department of Respiratory and critical care medicine NHC Key Laboratory of Pulmonary DiseasesUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430022China

To the Editor:Chronic obstructive pulmonary disease(COPD)is a condition that severely endangers human health.In 2018,Wang et al^([1])reported that there are approximately 100 million patients with COPD in China,with a 13.7%prevalence in people aged over 40 years.The disease severity,frequency of exacerbations,and comorbidities,which are commonly(30–57%)observed in patients with COPD,are the three most crucial elements affecting the economic and societal consequences of COPD.^([2])Hospitalizations for exacerbations are the main contributors to health care expenses.To reduce the clinical and financial burden of COPD,interventions are needed to slow the disease course,avoid exacerbations,and reduce comorbidities,such as approaches for improving the prognosis and treatment efficacy in COPD.

关键词： obstructive prognosis treatment

Secular trends of asthma mortality in China and the United States from 1990 to 2019

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第3期137卷 273-282页

作者： Xiaochen Li Mingzhou Guo Yang Niu Min Xie Xiansheng Liu department of pulmonary and critical care medicine Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China NHC Key Laboratory of Respiratory Diseases WuhanHubei 430030China

Background:Asthma imposes a large healthcare burden in China and the United States(US).However,the trends of asthma mortality and the relative risk factors have not been comparatively analyzed between the countries.The aim of this study was to compare the mortality and risk factors between China and the US.Methods:The deaths,and mortality rates of asthma in China and the US during 1990–2019 were obtained from the Global Burden of Disease Study 2019.The age–period–cohort model was used to estimate these mortality rates based on a log-linear scale with additive age,period,and cohort effects.The population attributable fractions of risk factors for asthma were estimated.Results:In 1990–2019,the asthma mortality rate was higher in China than in the US.The crude and age-standardized asthma mortality rates trended downward in both China and the US from 1990 to 2019.The decline in mortality was more obvious in China.Mortality gap between the two countries was narrowing.A sex difference in asthma mortality was observed with higher mortality in males in China and females in the US.The age effects showed that mortality increased with age in adults older than 20 years,particularly in the elderly.Downward trends were generally observed in the period and cohort rate ratios in both countries,with China experiencing a more obvious decrease.Smoking and high body mass index(BMI)were the leading risk factors for asthma mortality in China and the US,respectively.Mortality attributable to occupational asthmagens and smoking decreased the most in China and the US,respectively.Conclusions:In 1990–2019,the asthma mortality rate was higher in China than in the US;however,the mortality gap has narrowed.Mortality increased with age in adults.The improvements in asthma death risk with period and birth cohort were more obvious in China than in the US.Smoking,high BMI,and aging are major health problems associated with asthma control.The role of occupational asthmagens in asthma mortality underscores the importance of management and preventi

关键词： Asthma Mortality Global disease burden China the United States Age–period–cohort model

Clinical evolution of antisynthetase syndrome-associated interstitial lung disease after COVID-19 in a man with Klinefelter syndrome:A case report

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第6期12卷 1144-1149页

作者： Xiang-Xiang Wu Jian Cui Shi-Yao Wang Tian-Tian Zhao Ya-Fei Yuan Long Yang Wei Zuo Wen-Jian Liao department of Respiratory and critical care The First Affiliated HospitalJiangxi Medical CollegeNanchang UniversityNanchang 330006Jiangxi ProvinceChina China-Japan Friendship Jiangxi Hospital Nanchang 330006Jiangxi ProvinceChina department of pulmonary and critical care medicine Center of Respiratory MedicineChina-Japan Friendship HospitalBeijing 100029China

BACKGROUND This study presents a case of rapidly developing respiratory failure due to antisynthetase syndrome(AS)following coronavirus disease 2019(COVID-19)in a 33-year-old man diagnosed with Klinefelter syndrome(KS).CASE SUMMARY A 33-year-old man with a diagnosis of KS was admitted to the department of pulmonary and critical care medicine of a tertiary hospital in China for fever and shortness of breath 2 wk after the onset of COVID-19.Computed tomography of both lungs revealed diffuse multiple patchy heightened shadows in both lungs,accompanied by signs of partial bronchial inflation.Metagenomic next-generation sequencing of the bronchoalveolar lavage fluid suggested absence of pathogen.A biopsy specimen revealed organizing pneumonia with alveolar septal thickening.Additionally,extensive auto-antibody tests showed strong positivity for anti-SSA,anti-SSB,anti-Jo-1,and anti-Ro-52.Following multidisciplinary discussions,the patient received a final diagnosis of AS,leading to rapidly progressing respiratory failure.CONCLUSION This study underscores the clinical progression of AS-associated interstitial lung disease subsequent to viral infections such as COVID-19 in patients diagnosed with KS.

关键词： Antisynthetase syndrome COVID-19 Klinefelter syndrome Interstitial lung disease Anti-Jo-1 Case report

Primary biliary cholangitis presenting with granulomatous lung disease misdiagnosed as lung cancer:A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第2期12卷 354-360页

作者： Shan-Li Feng Jun-Yao Li Chun-Ling Dong department of Respiratory and critical care medicine The Second Hospital of Jilin UniversityChangchun 130041Jilin ProvinceChina

BACKGROUND There are few cases of pulmonary granulomatous changes secondary to primary biliary cirrhosis(PBC).No case of granulomatous lung disease secondary to PBC misdiagnosed as lung cancer had been reported.CASE SUMMARY A middle-aged woman presented with lung nodules and was misdiagnosed with lung cancer by positron emission tomography/computed tomography.She underwent left lobectomy,and the pathology of the nodules showed granulomatous inflammation,which was then treated with antibiotics.However,a new nodule appeared.Further investigation with lung biopsy and liver serology led to the diagnosis of PBC,and chest computed tomography indicated significant reduction in the pulmonary nodule by treatment with methylprednisolone and ursodeoxycholic acid.CONCLUSION Diagnosis of pulmonary nodules requires integrating various clinical data to avoid unnecessary pulmonary lobectomy.

关键词： Granulomatous lung diseases Primary biliary cirrhosis Differential diagnosis Misdiagnosis Lung cancer Case report

A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Frontiers of medicine 2024年第1期18卷 169-179页

作者： Xu Hao Zhiyao Bao Ranran Dai Xiaojing Wu Xin Li Muyin Zhang Hao Li Lili Xu Panpan Qiao Xuefei Liu Weiting Hu Ze Zhang Jie Fang Min Zhou Weiming Wang Jieming Qu department of Nephrology Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai200025China department of pulmonary and critical care medicine Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai200025China Institute of Respiratory Diseases Shanghai Jiao Tong University School of MedicineShanghai200025China department of Pharmacy Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai200025China

We aimed to investigate the safety and efficacy of nirmatrelvir/ritonavir(Paxlovid)therapy for hemodialysis-dependent patients with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.Thirteen hemodialysis patients infected with the Omicron variant of SARS-CoV-2 from April 3 to May 30,2022,were recruited.Laboratory parameters and chest CT(computed tomography)imaging were analyzed.The treatment group included six patients who received 150 mg/100 mg of Paxlovid orally once daily for 5 days,whereas the control group included seven patients who received basic treatment.No serious adverse reactions or safety events were recorded.Four control patients progressed to moderate disease,and none in the treatment group showed progression of chest CT findings(P<0.05).Paxlovid therapy tended toward early viral clearance and low viral load on Day 8.Moreover,83.3%of the patients in the treatment group and 57.1%of the patients in the control group turned negative within 22 days.In the Paxlovid treatment group,we found significantly increased levels of lymphocytes(P=0.03)and eosinophils(P=0.02)and decreased levels of D-dimer on Day 8 compared with those on Day 1.Paxlovid therapy showed a potential therapeutic effect with good tolerance in hemodialysis patients.The optimal dose and effectiveness evaluation must be further investigated in a largeer cohort.

关键词： Paxlovid hemodialysis SARS-CoV-2 viral load chest CT scan

Bronchoalveolar lavage fluid metagenomic next-generation sequencing assay for identifying pathogens in lung cancer patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

BIOCELL 2024年第4期48卷 623-637页

作者： JIYU WANG HUIXIA LI DEYUAN ZHOU LIHONG BAI KEJING TANG Division of pulmonary and critical care medicine The First Affiliated HospitalSun Yat-sen UniversityGuangzhouChina Institute of pulmonary Diseases Sun Yat-sen UniversityGuangzhouChina department of Pharmacy The First Affiliated HospitalSun Yat-sen UniversityGuangzhouChina

Background:For patients with lung cancer,timely identiﬁcation of new lung lesions as infectious or non-infectious,and accurate identiﬁcation of pathogens is very important in improving OS of patients.As a new auxiliary examination,metagenomic next-generation sequencing(mNGS)is believed to be more accurate in diagnosing infectious diseases in patients without underlying diseases,compared with conventional microbial tests(CMTs).We designed this study toﬁnd out whether mNGS has better performance in distinguishing infectious and non-infectious diseases in lung cancer patients using bronchoalveolar lavageﬂuid(BALF).Materials and Methods:This study was a real-world retrospective review based on electronic medical records of lung cancer patients with bronchoalveolar lavage(BAL)and BALF commercial mNGS testing as part of clinical care from 1 April 2019 through 30 April 2022 at The First Afﬁliated Hospital of Sun Yat-sen University.164 patients were included in this study.Patients were categorized into the pulmonary non-infectious disease(PNID)group(n=64)and the pulmonary infectious disease(PID)group(n=100)groups based onﬁnal diagnoses.Results:BALF mNGS increased the sensitivity rate by 60%compared to CMTs(81%vs.21%,p0.1).Among the patients with PID,bacteria were the most common cause of infection.Fungal infections occurred in 32%of patients,and Pneumocystis Yersini was most common.Patients with Tyrosine kinase inhibitors(TKIs)therapy possess longer overall survival(OS)than other anti-cancer agents,the difference between TKIs and immuno-checkpoint inhibitors(ICIs)was insigniﬁcant(median OS TKIs vs.ICIs vs.Anti-angiogenic vs.Chemo vs.Radiotherapy=76 vs.84 vs.61 vs.58 vs.60).Conclusions:our study indicates that BALF mNGS can add value by improving overall sensitivity in lung cancer patients with potential pulmonary infection,and was outstanding in identifying Pneumocystis infection.It could be able to help physicians adjust the follow-up treatmen

关键词： Lung cancer Bronchoalveolar lavage fluid Metagenomic next-generation sequencing Infectious diseases

Neural stem cell-derived exosomes regulate cell proliferation,migration,and cell death of brain microvascular endothelial cells via the miR-9/Hes1 axis under hypoxia

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Animal Models and Experimental medicine 2024年第1期7卷 24-35页

作者： Xiaojun Deng Xiaoyi Hu Shang Wang Hui Zhao Yaqin Wei Jiaqi Fu Wenhui Wu Jinming Liu Caicai Zhang Lili Wang Ping Yuan department of critical care medicine Shanghai Sixth People's HospitalShanghai Jiao Tong UniversityShanghaiChina department of Cardio-pulmonary Circulation Shanghai Pulmonary HospitalSchool of MedicineTongji UniversityShanghaiChina Institute of Bismuth Science University of Shanghai for Science and TechnologyShanghaiChina department of Physiology Hainan Medical University HaikouHainanChina department of Clinical Medical Laboratory Center Hangzhou Red Cross HospitalZhejiangChina

Background:Our previous study found that mouse embryonic neural stem cell(NSC)-derived exosomes(EXOs)regulated NSC differentiation via the miR-9/Hes1 axis.However,the effects of EXOs on brain microvascular endothelial cell(BMEC)dysfunction via the miR-9/Hes1 axis remain unknown.Therefore,the current study aimed to determine the effects of EXOs on BMEC proliferation,migration,and death via the miR-9/Hes1 axis.Methods:Immunofluorescence,quantitative real-time polymerase chain reaction,cell counting kit-8 assay,wound healing assay,calcein-acetoxymethyl/propidium iodide staining,and hematoxylin and eosin staining were used to determine the role and mechanism of EXOs on BMECs.Results:EXOs promoted BMEC proliferation and migration and reduced cell death under hypoxic conditions.The overexpression of miR-9 promoted BMEC prolifera-tion and migration and reduced cell death under hypoxic conditions.Moreover,miR-9 downregulation inhibited BMEC proliferation and migration and also promoted cell death.Hes1 silencing ameliorated the effect of amtagomiR-9 on BMEC proliferation and migration and cell death.Hyperemic structures were observed in the regions of the hippocampus and cortex in hypoxia-induced mice.Meanwhile,EXO treatment improved cerebrovascular alterations.Conclusion:NSC-derived EXOs can promote BMEC proliferation and migra-tion and reduce cell death via the miR-9/Hes1 axis under hypoxic conditions.Therefore,EXO therapeutic strategies could be considered for hypoxia-induced vascular injury.

关键词： brain microvascular endothelial cells exosomes Hes1 miR-9 neural stem cells

Impact of inhaled corticosteroid use on elderly chronic pulmonary disease patients with community acquired pneumonia

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第2期137卷 241-243页

作者： Xiudi Han Hong Wang Liang Chen Yimin Wang Hui Li Fei Zhou Xiqian Xing Chunxiao Zhang Lijun Suo Jinxiang Wang Guohua Yu Guangqiang Wang Xuexin Yao Hongxia Yu Lei Wang Meng Liu Chunxue Xue Bo Liu Xiaoli Zhu Yanli Li Ying Xiao Xiaojing Cui Lijuan Li Xuedong Liu Bin Cao department of pulmonary and critical care medicine Qingdao Municipal HospitalQingdaoShandong 266011China department of Nosocomial Infection Qingdao Municipal HospitalQingdaoShandong 266011China department of Infectious Diseases Nanjing Lishui People’s HospitalNanjingJiangsu 211213China department of pulmonary and critical care medicine National Clinical Research Center of Respiratory DiseasesCenter for Respiratory DiseasesChina-Japan Friendship HospitalBeijing 100020China department of Respiratory medicine Yan’an Hospital Affiliated to Kunming Medical UniversityKunmingYunnan 652199China department of Respiratory medicine Beijing Huimin HospitalBeijing 100054China department of pulmonary and critical care medicine Zibo Municipal HospitalZiboShandong 255000China department of Respiratory medicine Beijing Luhe HospitalCapital Medical UniversityBeijing 101149China department of pulmonary and critical care medicine Weifang No.2 People’s HospitalWeifangShandong 261599China department of Respiratory medicine Shandong University Affiliated Qilu Hospital(Qingdao)QingdaoShandong 266035China department of Respiratory medicine the 2nd Hospital of Beijing CorpsChinese Armed Police ForcesBeijing 100044China department of Infectious Disease Qingdao University Medical College Affiliated Yantai Yuhuangding HospitalYantaiShandong 100191China department of Respiratory medicine Rizhao Chinese Medical Hospital Affiliated to Shandong Chinese Medical UniversityRizhaoShandong 276800China department of Respiratory medicine Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical UniversityBeijing 100010China department of Occupational medicine and Toxicology Beijing Chao-Yang HospitalCapital Medical UniversityBeijing 100020China

To the Editor:With an aging global population,the incidences of community-acquired pneumonia(CAP)and chronic obstructive pulmonary disease(COPD)have signicantly increased.[1]Previous studies have conrmed that COPD and asthma are independently associated with the prevalence of CAP.The use of inhaled corticosteroid(ICS),the cornerstone of treatment for asthma,COPD with frequent acute exacerbations,and asthma-COPD overlap(ACO)may induce changes in the local lung microbiome and abnormal lung immunity,ultimately,causing a signicantly increased risk of pneumonia.However,in cases of pneumonia,the effect of the use of ICS on CAP mortality remains controversial.While data from one study favored the prior use of ICS,which was associated with a signicantly lower short-term mortality rate,[2]other studies have identied no impact on mortality.To date,data on the impact of the use of ICS on mortality,prehospitalization or during hospitalization,are scarce,particularly in the older population.Therefore,this multicenter,retrospective study explored the association between the use of ICS during hospitalization and short-term mortality in older patients with CAP and those with chronic pulmonary disease(CPD).

关键词： pneumonia patients immunity

Comparing the efficacy and safety of low,medium,and high dosages of selexipag for treating pulmonary hypertension:A systematic review and meta-analysis

在线全文

学校读者我要写书评

暂无评论

Animal Models and Experimental medicine 2024年第1期7卷 56-70页

作者： Shang Wang Yi Yan Jian Zhang Ping Yuan Ci-Jun Luo Hong-Ling Qiu Hui-Ting Li Jian Xu Lan Wang Tian-Lan Li Rong Jiang department of Cardio-pulmonary Circulation Shanghai Pulmonary HospitalSchool of MedicineTongji UniversityShanghaiChina Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease Shanghai Children's Medical CenterNational Children's Medical CenterShanghai Jiaotong University School of MedicineShanghaiChina department of Respiratory and critical care medicine The 416 Hospital of Nuclear IndustryThe Second Affiliated Hospital of Chengdu Medical CollegeChengduChina department of Hematology The Affiliated Hospital of Qingdao UniversityQingdaoChina

Background:The maintenance dosage of selexipag is categorized as low,medium or high.In order to assess the efficacy and safety of different dosages of selexipag for the risk stratification of pulmonary arterial hypertension(PAH),we performed a sys-tematic review and meta-analysis.Methods:Studies assessing PAH risk stratification indices,such as the World Health Organization functional class(WHO-FC),six-minute walk distance(6MWD),N-terminal pro-B-type natriuretic peptide(NT-proBNP)level,right atrial pressure(RAP),cardiac index(CI)and mixed venous oxygen saturation(SvO2),were included.Results:Thirteen studies were included.Selexipag led to improvements in the 6MWD(MD:24.20 m,95%CI:10.74-37.67),NT-proBNP(SMD:-0.41,95%CI:-0.79-0.04),CI(MD:0.47 L/min/m^(2),95%CI:0.17-0.77)and WHO-FC(OR:0.564,95%CI:0.457-0.697).Subgroup analysis demonstrated that all three dosages improved the 6MWD.A moderate dosage led to improvements in the CI(MD:0.30 L/min/m^(2),95%CI:0.15-0.46)and WHO-FC(OR:0.589,95%CI:0.376-0.922).Within 6 months of treatment,only the WHO-FC and CI were significantly improved(OR:0.614,95%CI:0.380-0.993;MD:0.30 L/min/m^(2),95%CI:0.16-0.45,respectively).More than 6 months of treatment significantly improved the 6MWD,WHO-FC and NT-proBNP(MD:40.87 m,95%CI:10.97-70.77;OR:0.557,95%CI:0.440-0.705;SMD:-0.61,95%CI:-1.17-0.05,respectively).Conclusions:Low,medium,and high dosages of selexipag all exhibited good effects.When treatment lasted for more than 6 months,selexipag exerted obvious effects,even in the low-dosage group.This finding is important for guiding individualized treatments.

关键词： individualized treatments meta-analysis prostacyclin receptor agonist risk stratification systematic review